Publication: Expanding research capacity and accelerating AIDS vaccine development in Asia
Issued Date
2008-07-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-49749131165
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.39, No.4 (2008), 766-784
Suggested Citation
Jean Louis Excler, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Yiming Shao, Linqi Zhang, Hiko Tamashiro, Saladin Qsmanov Expanding research capacity and accelerating AIDS vaccine development in Asia. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.39, No.4 (2008), 766-784. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/19627
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Expanding research capacity and accelerating AIDS vaccine development in Asia
Abstract
According to the Joint UN Program on AIDS (UNAIDS), an estimated 4.9 million adults and children are living with HIV in Asia and the Pacific. Refinement and development of existing and new prevention and treatment technologies - including safe, effective, and accessible AIDS vaccines - are urgent public health priorities. The Asian region faces several challenges for AIDS vaccine development. There are multiple genetic variants of HIV-1 driving the epidemic in the region and too few vaccine candidates in the pipeline targeting those subtypes. Low HIV incidence throughout the region means that trial sites must recruit larger numbers of volunteers and shift their focus to higher-risk populations where incidence is higher. Also, the cultural, economic, and political diversity of the region may render collaboration very complex, but also beneficial at a regional level. Recognizing that collaborating as a region could foster and accelerate AIDS vaccine development, participants at the Sapporo International Consultation recommended that an AIDS Vaccine Asian Network (AVAN) be created to facilitate interactions between donors and funding opportunities, increase regional clinical trial and production capacity, support region-specific advocacy and communication strategies, contribute to the Global HIV Vaccine Enterprise Scientific Plan, prepare a regional approach for future vaccine deployment, and develop a regional platform for clinical trials including harmonized legal, regulatory, and ethical frameworks.